BVF Inc. IL Sells 282,240 Shares of Palvella Therapeutics, Inc. $PVLA

BVF Inc. IL lowered its stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) by 24.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 879,009 shares of the company’s stock after selling 282,240 shares during the period. Palvella Therapeutics accounts for approximately 3.1% of BVF Inc. IL’s portfolio, making the stock its 10th biggest holding. BVF Inc. IL owned 7.42% of Palvella Therapeutics worth $92,006,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Aberdeen Group plc acquired a new stake in Palvella Therapeutics in the 3rd quarter worth about $3,212,000. First Light Asset Management LLC acquired a new stake in Palvella Therapeutics in the 3rd quarter worth about $33,949,000. Suvretta Capital Management LLC boosted its stake in Palvella Therapeutics by 15.1% in the 3rd quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after buying an additional 107,937 shares during the last quarter. Apis Capital Advisors LLC acquired a new stake in Palvella Therapeutics in the 3rd quarter worth about $627,000. Finally, Jennison Associates LLC boosted its stake in Palvella Therapeutics by 262.4% in the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock worth $40,558,000 after buying an additional 280,573 shares during the last quarter. 40.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. BTIG Research raised their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Chardan Capital reissued a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. HC Wainwright raised their price target on Palvella Therapeutics from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Stephens reissued an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Mizuho raised their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Palvella Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $199.53.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $112.63 on Thursday. The company has a market cap of $1.62 billion, a P/E ratio of -27.01 and a beta of -0.15. Palvella Therapeutics, Inc. has a one year low of $20.20 and a one year high of $151.18. The business’s 50-day simple moving average is $118.97 and its 200 day simple moving average is $108.85.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Analysts predict that Palvella Therapeutics, Inc. will post -5.26 earnings per share for the current year.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.